1. Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  2. LXR

LXR

LXRs (Liver X Receptor α and β) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors. LXRs are oxysterol-activated transcription factors that upregulate a suite of genes that together promote coordinated mobilization of excess cholesterol from cells and from the body. The LXRs, like other nuclear receptors, are anti-inflammatory, inhibiting signal-dependent induction of pro-inflammatory genes by nuclear factor-κB, activating protein-1, and other transcription factors.

LXRα is expressed predominately in some tissues, including the liver, kidney, macrophages, and adipose tissue. However, LXRβ is ubiquitously expressed. Activating LXRα (mainly expressed in liver) results in high triglyceride production, and growing evidence suggests that selective LXRβ agonists can reduce this side effect.

LXR Related Products (41):

Cat. No. Product Name Effect Purity
  • HY-10627A
    GW3965 hydrochloride Agonist 99.92%
    GW3965 hydrochloride is a potent and selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively[1][2][3].
  • HY-108688
    GSK2033 Antagonist 98.22%
    GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively.
  • HY-10626
    T0901317 Agonist 99.89%
    T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα[1]. T0901317 activates FXR with an EC50 of 5 μM[2]. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively[3]. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice[4][5].
  • HY-16972
    SR9243 Antagonist 98.88%
    SR9243 is a liver-X-receptor (LXR) inverse agonist that induces LXR-corepressor interaction.
  • HY-N2371
    27-Hydroxycholesterol Agonist
    27-Hydroxycholesterol (27-OHC) is a selective estrogen receptor modulator and an agonist of the liver X receptor.
  • HY-W754708
    Ouabagenin Activator
    Ouabagenin is a naturally occurring LXR ligand with LXR selective agonist activity. Ouabagenin acts as an EC 3.6.3.9 (Na(+)/K(+)- transport ATPase) inhibitor[1][2].
  • HY-W040150
    (24S,25)-Epoxycholesterol Agonist
    24S,25-Epoxycholesterol is an agonist for Liver X Receptor (LXR). 24S,25-Epoxycholesterol exhibits properties in regulating the cholesterol efflux[1], inhibiting tumor growth against gastric cancer and glioblastoma[2][3] and inducing apoptosis in BMMC cells[5].
  • HY-N12619
    12R,13S-Dihydroxyfumitremorgin C Agonist
    12R,13S-Dihydroxyfumitremorgin C (compound 1) is a LXRα agonist[1].
  • HY-125772
    Acetyl podocarpic acid anhydride Agonist
    Acetyl podocarpic acid anhydride is a potent, semisynthetic liver X receptor(LXR) agonist derived from extracts of the mayapple. Acetyl podocarpic acid anhydride has the potential to be useful for the prevention and research of atherosclerosis, especially in the context of low HDL levels[1].
  • HY-152262
    LXRβ agonist-4 Agonist 99.74%
    LXRβ agonist-4 is a potent, orally active Liver X receptors (LXRs) agonist with an IC50 value of 0.0078 μM for LXRβ. LXRβ agonist-4 inhibits RANKL-induced osteoclast differentiation and bone resorption. LXRβ agonist-4 can be used in research of osteoporosis[1].
  • HY-N2509
    Iristectorigenin B Agonist 99.49%
    Iristectorigenin B (Iristectrigenin B) is a liver X receptor (LXR) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β[1].
  • HY-160038
    GAC0003A4 Degrader
    GAC0003A4 is an LXR inverse agonist that inhibits LXR transcriptional activity. GAC0003A4 also efficiently degrades LXRβ protein. GAC0003A4 has the potential to be used in advanced pancreatic cancer and other refractory malignancies[1].
  • HY-123148
    IMB-808 Agonist 99.85%
    IMB-808 is a potent LXRα/β dual agonist with EC50 values of 0.53 μM and 0.15 μM (0.15 μM, using GAL4-pGL4-luc reporter plasmid) for LXRβ and LXRα, respectively. IMB-808 promotes expression of genes related to reverse cholesterol transport (ABCA1 and ABCG1). IMB-808 can be used as a promising agent for the prospective treatment of atherosclerosis research[1].
  • HY-123402
    GSK3987 Agonist 99.75%
    GSK3987 is a pan LXRα/β agonist with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c. GSK3987 induces cellular cholesterol efflux and triglyceride accumulation[1].
  • HY-109073
    Rovazolac Modulator 99.68%
    Rovazolac is a liver x receptor (LXR) modulator extracted from patent WO2013130892A1.
  • HY-146288
    LXR agonist 2 Agonist
    LXR agonist 2 (compound 18rr) is a potent LXR (liver X receptor) agonist. LXR agonist 2 can stabilize NCOA1 (co-activator), leading to LXR agonism[1].
  • HY-N3216
    Nagilactone B Agonist
    Nagilactone B is a liver X receptor (LXR) agonist.
  • HY-10629
    LXR-623 Agonist 99.48%
    LXR-623 is a brain-penetrant partial LXRα and full LXRβ agonist, with IC50s of 24 nM and 179 nM, respectively.
  • HY-139576B
    Larsucosterol (trimethylamine) Antagonist
    Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1[1][2][3].
  • HY-10627
    GW3965 Agonist
    GW3965 is a potent, selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively[1][2][3].